Clinical Trials Logo

EBV Related Carcinoma clinical trials

View clinical trials related to EBV Related Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05166577 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Start date: October 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma

NCT ID: NCT03923842 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours

Dern
Start date: June 30, 2019
Phase: Phase 2
Study type: Interventional

The aim of the present investigation is to test of the modulation obtained with denosumab as "priming" therapy before the start of chemotherapy and as concurrent therapy in a population of first line NPC recurrent/metastatic patients

NCT ID: NCT03314051 Completed - Clinical trials for Nasopharyngeal Carcinoma

Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

Start date: May 2, 2012
Phase: N/A
Study type: Observational

No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.